Gene therapies have revolutionized the way we treat diseases. However, patient urgency and high costs mean that more efficient production methods are needed.
AAV vectors are forecasted to be the dominant form of gene therapy because they have superior safety profiles. Therefore, solutions for rapid and scalable production will be key to bringing these therapies to patients.
Our partner, Synplogen, will share their experience in developing a robust and scalable upstream AAV platform for gene therapies.
In this webinar, you will hear from the Synplogen team about their:
Director, Medical Business Unit
In 2020, Shunsuke Saito joined Synplogen as a manager of business development. He is currently leading the medical business unit at Synplogen as a director and also researching AAV vector characterization & quality testing methods at Kobe University. Previously, he worked at Sumitomo Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc., focusing on formulation development.
Kentaro Hayashi, Ph.D.
Head, DNA Synthesis Business Unit
In 2020, Dr. Kentaro Hayashi joined Synplogen, and he is currently head of the DNA synthesis business unit, responsible for R&D, manufacturing, and sales activities for DNA synthesis service. Before joining Synplogen, he worked for medical affairs in the diabetes area of Eli Lilly, procuring valuable insights from leading physicians and building relationships within the medical community. Kentaro earned his Ph.D. from Keio University, where he focused on cancer research using a systems biology approach.
Yoshinori Takagi, Ph.D.
Officer, Medical Business Unit R&D
Dr. Yoshinori Takagi joined Synplogen in 2022, and he is currently leading the process development of plasmid DNA and viral as a head of the R&D team. Previously, he worked at Nippon Roche and Chugai Pharmaceutical Co., Ltd. He has a lot of experience in bioprocess development and has contributed to the commercialization and launch of some antibody drugs.
To continue reading please sign in or create an account.Don't Have An Account?